Fulgent Genetics, Inc. (FLGT): who owns it and who trades it
As of Nov 16, 2026, FLGT insiders reported 15 open-market sales worth $678K and no purchases in the last 12 months, with 0% of the sale value made under pre-set 10b5-1 plans. The largest seller was Jian Xie (President), with $505K. 4 of the 50 famous funds we follow held it at their last quarter end.
Latest filing Nov 16, 2026. From Form 4, 13F and Schedule 13D/G filings.
At a glance
Who is buying and selling Fulgent Genetics
From the latest filingsOverall: more selling than buying. Insiders and famous investors mostly sold. Funds was close to even.
Each group counts equally in the meter, by the number of buyers and sellers, not dollars. Insider sales under pre-set 10b5-1 plans are left out of it. From SEC, House and Senate filings; not advice.
Who owns FLGT
143 funds and institutions reported FLGT shares worth $329M at the end of Q2 2026, about 56% of the company. The largest holder is BlackRock, Inc. with 8.1%.
Funds and institutions (13F) 56%Everyone else 44%
10 largest owners, by share of the company
Top 20 owners
| Owner | Shares | % of company | Value | Change since Q1 2026 |
|---|---|---|---|---|
| BlackRock, Inc. | 2.29M | 8.05% | $46.9M | -18% |
| Acadian Asset Management LLC | 1.02M | 3.58% | $20.9M | -18% |
| Vanguard Capital Management LLC | 789,498 | 2.78% | $16.2M | -10% |
| Jacobs Levy Equity Management, Inc | 782,116 | 2.75% | $16M | +119% |
| JPMorgan Chase & Co | 756,558 | 2.66% | $15.5M | – |
| Diametric Capital, LP | 697,784 | 2.46% | $14.3M | +93% |
| Ameriprise Financial Inc | 670,084 | 2.36% | $13.8M | +19% |
| Dimensional Fund Advisors LP | 625,355 | 2.20% | $12.8M | -7% |
| Geode Capital Management, LLC | 521,014 | 1.83% | $10.7M | -11% |
| State Street Corp | 498,673 | 1.76% | $10.2M | -6% |
| Invenomic Capital Management LP | 498,287 | 1.75% | $10.2M | -18% |
| Two Sigma Investments, LP | 400,986 | 1.41% | $8.2M | +24% |
| Charles Schwab Investment Management Inc | 350,987 | 1.24% | $7.2M | -1% |
| Sixth Street Partners Management Company, L.P. | 350,987 | 1.24% | $7.2M | – |
| Millennium Management LLC | 320,910 | 1.13% | $6.6M | -20% |
| Goldman Sachs Group Inc | 307,940 | 1.08% | $6.3M | -1% |
| D. E. Shaw & Co., Inc. | 292,006 | 1.03% | $6M | -40% |
| Hrt Financial LP | 229,444 | 0.81% | $4.7M | +394% |
| Peapod Lane Capital LLC | 224,207 | 0.79% | $4.6M | +2% |
| Point72 Asset Management, L.P. | 211,708 | 0.75% | $4.3M | – |
From the SEC 13F data sets: every fund manager with over $100M must report its US stock holdings every 3 months, up to 45 days after the quarter ends. Owners are shown as they file, so one group (for example Vanguard) can appear under several names. Individuals, most insiders and smaller funds do not file 13F reports.
Insider trades
In the last 12 months, FLGT insiders reported $0 of open-market purchases and $678K of sales. 0% of the sale value was under a 10b5-1 plan, a schedule set up in advance.
Purchases and sales by month
Latest trades
| Date | Insider | Role | Type | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|---|
| Sep 2, 2026 | Hanlin Gao | Chief Scientific Officer | Sale | 1,673 | $19.66 | $32.9K | Form 4 |
| Sep 2, 2026 | Jian Xie | President | Sale | 2,127 | $19.66 | $41.8K | Form 4 |
| Aug 27, 2026 | Jian Xie | President | Sale | 1,193 | $19.91 | $23.8K | Form 4 |
| Aug 27, 2026 | Hanlin Gao | Chief Scientific Officer | Sale | 939 | $19.91 | $18.7K | Form 4 |
| Jun 2, 2026 | Jian Xie | President | Sale | 2,146 | $17.89 | $38.4K | Form 4 |
| Jun 2, 2026 | Hanlin Gao | Chief Scientific Officer | Sale | 1,688 | $17.89 | $30.2K | Form 4 |
| May 27, 2026 | Jian Xie | President | Sale | 1,201 | $17.60 | $21.1K | Form 4 |
| May 27, 2026 | Hanlin Gao | Chief Scientific Officer | Sale | 945 | $17.60 | $16.6K | Form 4 |
| Dec 2, 2025 | Jian Xie | President | Sale | 1,140 | $28.33 | $32.3K | Form 4 |
| Dec 2, 2025 | Hanlin Gao | Chief Scientific Officer | Sale | 1,075 | $28.33 | $30.5K | Form 4 |
| Nov 28, 2025 | Jian Xie | President | Sale | 1,198 | $29.57 | $35.4K | Form 4 |
| Nov 28, 2025 | Hanlin Gao | Chief Scientific Officer | Sale | 943 | $29.57 | $27.9K | Form 4 |
| Nov 24, 2025 | Jian Xie | President | Sale | 681 | $30.47 | $20.8K | Form 4 |
| Nov 24, 2025 | Hanlin Gao | Chief Scientific Officer | Sale | 535 | $30.47 | $16.3K | Form 4 |
| Nov 19, 2025 | Jian Xie | President | Sale | 10,000 | $29.10 | $291K | Form 4 |
Insiders by value traded
| Insider | Role | Bought | Sold | Last trade |
|---|---|---|---|---|
| Jian Xie | President and COO | – | $505K | Sep 2, 2026 |
| Hanlin Gao | Chief Scientific Officer | – | $173K | Sep 2, 2026 |
What this data shows, and what it doesn't
- Shows: open-market purchases and sales by officers, directors and 10%+ owners, reported on Form 4 within two business days of the trade.
- Leaves out: stock awards, option exercises, shares withheld for tax and gifts. These are not trades at a market price chosen by the insider.
- "plan" marks a sale made under a Rule 10b5-1 plan, a schedule set up in advance.
- Fund holders come from 13F reports, a snapshot at quarter end filed up to 45 days later.
- Filings are self-reported and can be amended. Each trade links to its original filing. Methodology
FLGT short interest
Moderate short interest. 7.3% of FLGT shares are sold short: about 1 share in 14. Over the last 12 reports the number of shares short went down 26%.
As a rough guide, under 5% is low, 5–10% is moderate, 10–20% is high and over 20% is very high.
As of Oct 30, 2026, 2.02M FLGT shares were sold short, 7.3% of the shares outstanding, down 5.4% from the report before. At the average daily volume of 258,478 shares, buying them all back would take about 7.8 trading days (days to cover).
Shares short, % of all shares
Days to cover
Every report
| Settlement date | Shares short | % of shares | Change | Avg daily volume | Days to cover |
|---|---|---|---|---|---|
| Oct 30, 2026 | 2.02M | 7.33% | -5% | 258,478 | 7.8 |
| Oct 15, 2026 | 2.13M | 7.75% | -5% | 287,789 | 7.4 |
| Sep 30, 2026 | 2.24M | 8.13% | -3% | 311,711 | 7.2 |
| Sep 15, 2026 | 2.32M | 8.42% | -2% | 345,550 | 6.7 |
| Aug 31, 2026 | 2.37M | 8.61% | -7% | 237,554 | 10.0 |
| Aug 14, 2026 | 2.56M | 9.29% | -0% | 274,276 | 9.3 |
| Jul 31, 2026 | 2.57M | 9.32% | -7% | 320,516 | 8.0 |
| Jul 15, 2026 | 2.75M | 9.70% | +5% | 240,837 | 11.4 |
| Jun 30, 2026 | 2.63M | 9.25% | -4% | 332,634 | 7.9 |
| Jun 15, 2026 | 2.73M | 9.61% | -3% | 413,008 | 6.6 |
| May 29, 2026 | 2.80M | 9.86% | +3% | 558,629 | 5.0 |
| May 15, 2026 | 2.72M | 9.58% | +9% | 695,550 | 3.9 |
Short sellers borrow shares and sell them, hoping to buy them back for less. A high number means many such bets are open. It does not say where the price will go. Source: FINRA equity short interest, reported by brokers twice a month (positions on the 15th and the last business day) and published about 7 business days later. % of shares uses the share count on the company's latest SEC filing. What short interest means · Most shorted stocks
Fulgent Genetics company events
Fulgent Genetics filed 9 reports on Form 8-K in the last 12 months, 1 of them about an important change (leadership). The latest was on Nov 5, 2026.
- Nov 5, 2026ResultsReleased financial results. Filing
- Jul 30, 2026ResultsReleased financial results. Filing
- Jun 2, 2026AnnouncementFulgent Genetics, Inc. issued a press release announcing that the Company will present updated data in the Head and Neck Cancer Track during the American Society of Clinical Oncology (ASCO) 2026 Annual Meeting Rapid Oral Abstract Session based on the Company's full abstract entitled “ FID-007 in… Filing
- May 21, 2026AnnouncementFulgent Genetics, Inc. issued a press release announcing that the Company's full abstract entitled “ FID-007 in combination with cetuximab in recurrent or metastatic (R/M) head and neck squamous cell carcinoma (HNSCC), Abstract #6020 ”, presenting interim data from the Company's open-label… Filing
- May 14, 2026LeadershipAt the 2026 Annual Meeting of Stockholders of Fulgent Genetics, Inc., the Company’s stockholders approved the Fulgent Genetics, Inc. 2026 Equity Incentive Plan. Filing
- May 1, 2026ResultsReleased financial results. Filing
- Mar 17, 2026DealOf this Current Report on Form 8-K relating to the Lease and Lease Assignment (each as defined in Item 2.01 of this Current Report on Form 8-K) is incorporated by reference into this Item 1.01. Filing
- Feb 27, 2026ResultsReleased financial results. Filing
- Dec 22, 2025AgreementInform Diagnostics, Inc., a wholly owned subsidiary of Fulgent Genetics, Inc., entered into a Purchase and Sale Agreement with Bako Pathology LP, Bako Pathology Holdings Corp., BPA Holding Corp., Dermatopathology Experts, LLC, and Fulgent Therapeutics, LLC (solely for purposes of Section 11.16 (and… Filing
From 8-K reports, which a company must file within 4 business days of an important event. Where a report is about a change such as a new CEO, the sentence is the first one from the report itself, shortened. Each row links to the original filing. Company events this week
Fulgent Genetics financials
Famous investors that hold FLGT
4 of the 50 well-known investors we track reported holding FLGT in their latest 13F filing. The largest position is Paul Tudor Jones's, worth $5.8M.
Position size
All holders
| Fund | Quarter | Shares | Value | Of portfolio | Change |
|---|---|---|---|---|---|
| Paul Tudor Jones · Tudor Investment Corp | Q3 2026 | 262,344 | $5.8M | 0.0% | +221% |
| Ken Griffin · Citadel Advisors | Q3 2026 | 125,385 | $2.8M | 0.0% | -28% |
| Israel Englander · Millennium Management | Q3 2026 | 90,484 | $2M | 0.0% | -72% |
| Steve Cohen · Point72 Asset Management | Q3 2026 | 54,318 | $1.2M | 0.0% | -74% |
From 13F reports: a snapshot at quarter end, filed up to 45 days later. Change compares with the quarter before.
Questions about Fulgent Genetics, Inc. (FLGT) stock
Who owns the most FLGT stock?
The largest reported owner of Fulgent Genetics, Inc. (FLGT) is BlackRock, Inc., with 8.1% of the company. In total, 143 funds and institutions reported holding FLGT at the end of Q2 2026, together about 56% of the shares. See the largest owners.
Are FLGT insiders buying or selling?
In the last 12 months, FLGT insiders reported no open-market purchases and 15 sales worth $678K. The latest trade was on Sep 2, 2026. See every trade.
What is the short interest in FLGT?
As of Oct 30, 2026, 2.02M FLGT shares were sold short, 7.3% of the shares outstanding, down 5.4% from the report before. At the average daily volume of 258,478 shares, buying them all back would take about 7.8 trading days (days to cover). See the history.
Which famous investors hold FLGT?
4 of the 50 well-known investors we track reported FLGT in their latest 13F filing, including Paul Tudor Jones, Ken Griffin, Israel Englander. The largest position is worth $5.8M. See all holders.
Source: SEC Form 4 (insiders, filed within 2 business days), 13F (funds, up to 45 days after quarter end) and Schedule 13D/13G filings. Only open-market purchases (code P) and sales (code S) are shown. Data only, not investment advice. How we collect it.